ARPA-H announced it will spend up to $160 million on THRIVE, an effort to develop custom gene-editing treatments for rare diseases. The program will fund seven teams, each with an explicit objective to start clinical trials by year three. The initiative is positioned as a “moonshot” push for bespoke therapies, emphasizing speed to clinic and multiple organ-system targets. The structure aims to create parallel execution across disease areas while maintaining timelines that translate preclinical progress into first-in-human studies. For biotech stakeholders, THRIVE adds a sizable, deadline-driven funding channel for gene-editing platform developers and disease teams competing to establish early clinical proof.